타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | mirvetuximab soravtansine-gynx (Elahere, IMGN853, mirvetuximab-soravtansine-gynx) AbbVie / ImmunoGen·FRα (folate receptor alpha) 32 trials | |||
|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Elahere (mirvetuximab soravtansine-gynx) | Sirolimus | Cyclosporine |
Overview Company | Roche / Genentech | AbbVie / ImmunoGen | Prevail Therapeutics | Amsterdam Molecular Therapeutics |
Overview Modality | ADC | ADC | ADC | ANTIBODY |
Overview Target | FRα | FRα (folate receptor alpha) | FRα | FRα |
Overview Indication | Large B-Cell Lymphoma | FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer | Parkinson Disease | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_3 | APPROVED | APPROVED | PHASE_3 |
Overview Status | RECRUITING | APPROVED | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development | FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression. | — | — |
Positioning Known limitation | resistance to POLA in vivo | FRα downregulation and multidrug-resistance transporter upregulation. | — | — |
Positioning Development positioning | — | 2L–4L platinum-resistant | — | — |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic | DM4 (maytansinoid, tubulin inhibitor) | — | — |
Technology Linker | linker, or payload that have limited their development | Cleavable sulfo-SPDB disulfide, DAR ~3.5 | — | — |
Technology DAR | — | DAR 3.5 | — | — |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity. | target synergy, effectively inhibits the PI3K pathway | target interactions (TNF, NF‑κB, STAT3, IL-1β, AKT1, IL-6, Src) and pathways (IL-17, PI3K-Akt, TNF signaling |
MoA Biomarker | CD20 expression | FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining. | biomarkers or targeted therapies to guide management | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Rat | — | — |
Toxicology Animal (cat.) | Mouse, Rat, NHP | — | — | — |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | — | — |
Toxicology CRS | — | N/A | — | — |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | — | — |
Clinical Selected reported efficacy | — | ORR 42% | — | — |
Clinical Reported ORR | — | 42% vs 16% (chemotherapy; rounded in NCI report) | — | — |
Clinical Reported PFS | — | 5.6 months vs 4.0 months (chemotherapy) | — | — |
Clinical Reported OS | — | 16.5 months vs 12.8 months (chemotherapy) | — | — |
Clinical Result source | — | NCI approval analysis 2024 — MIRASOL (NCT04209855) | — | — |
Clinical Program phase | PHASE_3 | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | NCT04209855 | — | — |
Preclinical Animal (cat.) | Rat | — | — | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | mirvetuximab soravtansine-gynx (Elahere, IMGN853, mirvetuximab-soravtansine-gynx) AbbVie / ImmunoGen·FRα (folate receptor alpha) 32 trials | |||
|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Elahere (mirvetuximab soravtansine-gynx) | Sirolimus | Cyclosporine |
Overview Company | Roche / Genentech | AbbVie / ImmunoGen | Prevail Therapeutics | Amsterdam Molecular Therapeutics |
Overview Modality | ADC | ADC | ADC | ANTIBODY |
Overview Target | FRα | FRα (folate receptor alpha) | FRα | FRα |
Overview Indication | Large B-Cell Lymphoma | FRα-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer | Parkinson Disease | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_3 | APPROVED | APPROVED | PHASE_3 |
Overview Status | RECRUITING | APPROVED | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Approved (flag incomplete) | Investigational |
Positioning Key differentiator | unique toxicities related to the antigen target, linker, or payload that have limited their development | FRα is overexpressed in ovarian cancer but sparse in normal tissue, and the label requires IHC-confirmed expression. | — | — |
Positioning Known limitation | resistance to POLA in vivo | FRα downregulation and multidrug-resistance transporter upregulation. | — | — |
Positioning Development positioning | — | 2L–4L platinum-resistant | — | — |
Technology Payload | vedotin, rituximab, cyclophosphamide, doxorubic | DM4 (maytansinoid, tubulin inhibitor) | — | — |
Technology Linker | linker, or payload that have limited their development | Cleavable sulfo-SPDB disulfide, DAR ~3.5 | — | — |
Technology DAR | — | DAR 3.5 | — | — |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Binds FRα, internalizes via receptor-mediated endocytosis, and releases DM4 after disulfide reduction; tubulin disruption causes mitotic arrest, with lipophilic S-methyl-DM4 giving bystander activity. | target synergy, effectively inhibits the PI3K pathway | target interactions (TNF, NF‑κB, STAT3, IL-1β, AKT1, IL-6, Src) and pathways (IL-17, PI3K-Akt, TNF signaling |
MoA Biomarker | CD20 expression | FRα IHC (VENTANA FOLR1 RxDx), PS2+ scoring with ≥75% of tumor cells staining. | biomarkers or targeted therapies to guide management | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Rat | — | — |
Toxicology Animal (cat.) | Mouse, Rat, NHP | — | — | — |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | — | — |
Toxicology CRS | — | N/A | — | — |
Clinical Safety signal | Hepatotoxicity: Monitor liver enzymes and bilirubin | Boxed warning for ocular toxicity — keratopathy, blurred vision, and dry eye. Peripheral neuropathy, nausea, and fatigue are also common. | — | — |
Clinical Selected reported efficacy | — | ORR 42% | — | — |
Clinical Reported ORR | — | 42% vs 16% (chemotherapy; rounded in NCI report) | — | — |
Clinical Reported PFS | — | 5.6 months vs 4.0 months (chemotherapy) | — | — |
Clinical Reported OS | — | 16.5 months vs 12.8 months (chemotherapy) | — | — |
Clinical Result source | — | NCI approval analysis 2024 — MIRASOL (NCT04209855) | — | — |
Clinical Program phase | PHASE_3 | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | — | NCT04209855 | — | — |
Preclinical Animal (cat.) | Rat | — | — | Mouse |
추천 비교
추천 비교